11-07-2007, 10:28 PM
Another long one & the disease word again.....not quite certain if they're talking about a cure??
Researchers Present Alzheimer’s and Autism Breakthroughs
Researchers Present Alzheimer’s and Autism Breakthroughs
Quote:
Newswise — At The Society for Neuroscience annual meeting, Dr. Giulio Maria Pasinetti, M.D., Ph.D., Professor of Psychiatry and Neuroscience, Geriatrics and Adult Development and Director of the Center of Excellence for Research in Complementary and Alternative Medicine in Alzheimer's disease at Mount Sinai School of Medicine in New York presented the following new breakthrough research findings for Alzheimer’s disease and other brain disorders.
.>snip<
Personalized Medicine in Autistic Spectrum Disorder
Autism spectrum disorders often remain unrecognized and undiagnosed until, or after late preschool age due to the lack of appropriate and selective screening procedures in young children, particularly among toddlers. Development of clinically accessible molecular signatures may improve disease diagnosis at a young age and promote early-individualized treatment, which may ultimately improve the outcome for autistic children and their families. Using a combination of microRNA (miRNA) and proteomic technology platforms, Dr. Pasinetti’s laboratory at Mount Sinai used novel molecular signatures as potential practical and accurate diagnostic assay for Autism spectrum disorders. Dr. Pasinetti reports the identification of two sets of miRNA in circulating peripheral blood monocyte cells (PBMC) which selectively and redundantly target and influence the activity of gene products previously implicated in abnormal brain structural/behavioral abnormalities and mitochondrial activities in high functioning autistic spectrum disorder subjects. The development of clinically accessible molecular signatures such as these identified miRNA may improve disease diagnosis at a young age and promote early-individualized treatment, which may ultimately improve the outcome for autistic children and their families.
Dr. Pasinetti anticipates that his work will lead to earlier interventions and more specific treatments predicated on the individual’s specific biochemical fingerprint. This is in stark contrast to current medical practice. Personalized medicine offers the alluring promise and potential of uncovering the largely ‘unseen’ details in autistic spectrum disorders causality and selective response to drug treatments.
.>snip<
Personalized Medicine in Autistic Spectrum Disorder
Autism spectrum disorders often remain unrecognized and undiagnosed until, or after late preschool age due to the lack of appropriate and selective screening procedures in young children, particularly among toddlers. Development of clinically accessible molecular signatures may improve disease diagnosis at a young age and promote early-individualized treatment, which may ultimately improve the outcome for autistic children and their families. Using a combination of microRNA (miRNA) and proteomic technology platforms, Dr. Pasinetti’s laboratory at Mount Sinai used novel molecular signatures as potential practical and accurate diagnostic assay for Autism spectrum disorders. Dr. Pasinetti reports the identification of two sets of miRNA in circulating peripheral blood monocyte cells (PBMC) which selectively and redundantly target and influence the activity of gene products previously implicated in abnormal brain structural/behavioral abnormalities and mitochondrial activities in high functioning autistic spectrum disorder subjects. The development of clinically accessible molecular signatures such as these identified miRNA may improve disease diagnosis at a young age and promote early-individualized treatment, which may ultimately improve the outcome for autistic children and their families.
Dr. Pasinetti anticipates that his work will lead to earlier interventions and more specific treatments predicated on the individual’s specific biochemical fingerprint. This is in stark contrast to current medical practice. Personalized medicine offers the alluring promise and potential of uncovering the largely ‘unseen’ details in autistic spectrum disorders causality and selective response to drug treatments.
